Figure 6

Statins have a proviral role in WNV-infected eNPCs. WNV-infected eNPCs (MOI 5 × 10^–3) were treated with 1 or 10 µM atorvastatin, fluvastatin, simvastatin or lovastatin. A Photomicrographs of WNV-infected eNPCs treated or not with statins. Cells were immunostained with anti-WNV-E3 antibody (red). Nuclei were stained with DAPI (blue). B Automated enumeration of total cell number based on DAPI staining and percentage of infected cells based on immunostaining with anti-WNV-E3 antibody. Normalisation to control (non-treated WNV-infected eNPCs). Quantification of C viral RNA and D virus titers in supernatant. Results are representative of 3 independent experiments performed in quadruplicate (A, B) and are pooled from 2 independent experiments performed in triplicate (C, D). They are expressed as the mean ± SD. Comparison between treated and non-treated WNV-infected eNPCs was performed with a two-tailed unpaired Mann Whitney test with p-values significant when *p < 0.05, **p < 0.01. ATO: atorvastatin, FLU: fluvastatin, SIM: simvastatin, LOVA: lovastatin.